A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
Brigham and Women's Hospital · Harvard University · +12 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
734
total citations
- FWCI
- 32.16
- Percentile
- 100%
- References
- 80
Citations per year
Authors
39- PAPatrick A. OttCorresponding
Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center
- SHSiwen Hu‐Lieskovan
University of California, Los Angeles
- BCBartosz Chmielowski
University of California, Los Angeles
- RGRamaswamy Govindan
Washington University in St. Louis
- ANAung Naing
The University of Texas MD Anderson Cancer Center
Topics & keywords
Topics
Keywords
- Immunogenicity
- Immunology
- Cancer vaccine
- Lung cancer
- Cancer
- Cytotoxic T cell
- Biology
- Immunotherapy
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.